Perampanel: a new agent for adjunctive treatment of partial seizures (Q38178768)

30 August 2017

title

Perampanel: a new agent for adjunctive treatment of partial seizures (English)

1 reference

30 August 2017

1 reference

Michele A Faulkner

1 reference

30 August 2017

publication date

1 February 2014

1 reference

American Journal of Health-System Pharmacy

30 August 2017

published in

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

191-198

1 reference

The epidemiology of the epilepsies

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

31 March 2020

Drug-resistant epilepsy

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

The natural history of epilepsy: an epidemiological view.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Revisiting AMPA receptors as an antiepileptic drug target

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Perampanel: as adjunctive therapy in patients with partial-onset seizures

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Molecular targets for antiepileptic drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Glutamate receptor ion channels

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

The tetrameric structure of a glutamate receptor channel

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Implications for neuroprotective treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

AMPA receptor-mediated neurotoxicity: role of Ca2+ and desensitization

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Epilepsy: perampanel-new promise for refractory epilepsy?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Novel treatment options for epilepsy: focus on perampanel.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

Tolerability and safety of perampanel: two randomized dose-escalation studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP130203

31 March 2020

Identifiers

DOI

10.2146/AJHP130203

1 reference

30 August 2017

1 reference